The hazard ratios for PCS had no significant difference between the two groups regarding age, sex, presence of body weight loss, ECOG performance status, comorbidity, tumor stage, elevation of carcinoembryonic antigen level, and regimen of first‐line chemotherapy. The gene discussed is CEACAM5; the disease is neoplasm.